
MSK Research Highlights, June 29, 2023
New MSK research discovered ferroptosis regulators that suggest therapeutic opportunities against hormone receptor-positive cancers; examined how tumor-associated macrophages might be turned against cancer; acquired new insights into joint inflammation in rheumatoid arthritis; developed a systems-level platform called epichaperomics to map changes in interactors among thousands of proteins involved in cancer-related processes; and investigated how artificial intelligence could help diagnose an invasive form of breast cancer.
In the Lab

More Evidence that Cellular ‘Death by Iron’ Could Be Promising Avenue of Cancer Treatment
Cancers with certain mutations are vulnerable to ferroptosis, a form of iron-dependent cell death.
Finding

Scientists See Potential in Cellular 'Death by Iron' for Cancer Treatment
This form of cell death is called ferroptosis, and certain cancer cells are especially vulnerable to it.
Novel Regulation of the Common Tumor Suppressor PTEN
Researchers led by scientists at Memorial Sloan Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of <i>PTEN</i> function. The findings from two related studies are published in the January 12 issue of <i>Cell</i>.

At Work: Cell Biologist Xuejun Jiang
Xuejun Jiang heads a laboratory at the Sloan Kettering Institute, where he continues to help unlock the mysteries of programmed cell death.